Andre Watson

Chairman & CEO @Ligandal, Biomaterials Scientist and Nanoengineer, Forbes 30Under30 in Healthcare

Andre Watson is a prominent figure in the field of genetic medicine and nanotechnology. Here are the key details about him:

Professional Background

Andre Watson is the Founder and CEO of Ligandal, a precision genetic medicine company that utilizes nanotechnology to develop targeted and personalized therapies.1 His expertise lies in:

Targeted gene delivery
Nano- and biomaterials
Computational modeling of peptides
Binding simulations
Immunoengineering
CRISPR and TALEN-based gene editing

Current Roles

Founder, Chairman & CEO of Hyperstition Incorporated1
Founder and CEO of Ligandal (since July 2016)1
Advisor at Avro Life Science (since October 2017)1

Notable Achievements

Forbes 30 Under 30 honoree in Healthcare2
Developed peptide-based delivery systems for CRISPR, RNA, DNA, siRNA, and various genes or proteins1

Education

Andre Watson attended Rensselaer Polytechnic Institute.1

Current Focus

At Ligandal, Watson is currently working on:

Developing ultra-rapid therapeutics and vaccines for outbreaks and pandemics
Immuno-oncology research
Rare genetic diseases treatments
Delivering a peptide-based cure for COVID-19 (SARS-CoV-2 coronavirus)1

Additional Skills

Piano Performance
Technology
Innovation Engineering
Cell Biology
Powerlifting
Martial Arts3

Andre Watson's work at Ligandal and his advisory role at Hyperstition Incorporated demonstrate his commitment to advancing the field of genetic medicine and nanotechnology, with a focus on developing innovative solutions for complex medical challenges.